Effect of atorvastatin and rosuvastatin on 25-hydroxy vitamin d levels in newly diagnosed South Indian dyslipidemic subjects
A randomized, open-label, single center study
Keywords:
Dyslipidemia, Statins, HMG-CoA reductase inhibitors, Atorvastatin, Rosuvastatin, 25-OHD concentration, Vitamin-D levelsAbstract
Background: Statins are one of the mainstay treatment modality for the people suffering from dyslipidemia. Statins reduce the cholesterol bio-synthesis by ß-hydroxy-ß-methyl glutaryl Co-A (HMG-CoA) reductase inhibition which is rate-limiting enzyme. It also affects the Vit-D levels as metabolism of cholecalciferol and cholesterol are interrelated. Objectives: Effect of atorvastatin/ rosuvastatin on 25-hydroxy Vitamin-D (25OHD) concentrations among subjects with newly diagnosed dyslipidemia. Materials and Methods: Prospective randomized, open-label, parallel group study. Lipid and 25OHD levels are measured at baseline and end of 6 months after statin treatment. One group received atorvastatin and another study group received rosuvastatin for 6 months. Results: Mean 25OHD concentrations are 32.0±4.7, 31.7±4.8 and 32.9±4.9 in the control, atorvastatin and rosuvastatin groups respectively. Both atorvastatin and rosuvastatin groups, except TGs, all the lipid parameters and 25OHD has showed significant difference (<0.001) from baseline to end-line repeated parameters. All the study participants were well tolerated and no one discontinued the drug due to drug-related adverse reactions. Conclusion: Participants with atorvastatin treated group showed significant reduction in 25OHD concentrations. In addition, 25OHD concentrations are dependent on statin efficacy.
Downloads
References
World Health Organisation. India - NCD Profile [Internet]. 2014. Available from: http://www.who.int/ nmh/countries/ind_en.pdf?ua=1
Ajay V. S and Prabhakaran D. Coronary heart disease in Indians: Implications of the INTERHEART study. Indian. J. Med. Res. 2010;132:561–566.
Raja S, Mohapatra S, Kumar J. S and Rani R. J. Prescription patterns of hypolipidaemic drugs in a tertiary care teaching hospital of southern India. J. Clin. Diagn. Res. 2014;8:HC01-HC03.
Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 2005;19:117–125.
Shitara Y and Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 2006;112:71–105.
Abd T. T and Jacobson T. A. Statin-induced myopathy: a review and update. Expert. Opin. Drug. Saf. 2011;10:373–387.
Sahebkar A, Reiner Z, Simental-Mendia L. E, Ferretti G, Della Corte C and Nobili V. Impact of Statin Therapy on Plasma Vitamin D Levels: A Systematic Review and Meta-Analysis. Curr. Pharm. Des. 2017;23:861–869.
Zittermann A and Pilz S. Vitamin D and Cardiovascular Disease: An Update. Anticancer. Res. 2019;39:4627–4635.
Riche K. D, Arnall J, Rieser K, East H. E and Riche D. M. Impact of vitamin D status on statin-induced myopathy. J. Clin. Transl. Endocrinol. 2016;6:56–59.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes. Care. 2014;37 Suppl 1:S81-S90.
Grundy S. M, Cleeman J. I, Merz C. N, Brewer H. B, Clark L. T and Hunninghake D. B, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Am. Coll. Cardiol. 2004;44:720–732.
Menon A. S, Kotwal N, Singh Y and Girish R. Statins: Cholesterol guidelines and Indian perspective. Indian. J. Endocrinol. Metab. 2015;19:546–553.
Mangravite L. M, Thorn C. F and Krauss R. M. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics. J. 2006;6:360–374.
Chen Y, Zhang X, Pan B, Jin X, Yao H and Chen B, et al. Modified formula for calculating low-density lipoprotein cholesterol values. Lipids. Health. Dis. 2010;9:9–52.
Kiebzak G. M, Leamy L. J, Pierson L. M, Nord R. H and Zhang Z. Y. Measurement precision of body composition variables using the lunar DPX-L densitometer. Clin. Densitom. 2000;3:35–41.
Russo M. W, Hoofnagle J. H, Gu J, Fontana R. J, Barnhart H and Kleiner D. E, et al. Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network. Hepatology. 2014;60:679–686.
Demir C. C, Mousa U and Anil C. Effects of atorvastatin and rosuvastatin therapy on serum 25-hydroxyvitamin D levels: A comparative study 13th European Congress of Endocrinology. Endocr Abstr. 2011;26:548.
Radhakrishnan A. Statin therapy and Vitamin D. Int. J. Basic. Clin. Pharmacol. 2015;4:1113–1117.
Anagnostis P, Adamidou F, Slavakis A, Polyzos S. A, Selalmatzidou D and Panagiotou A, et al. Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study. Open. Cardiovasc. Med. J. 2014;8:55–60.
Thabit A, Alhifany A, Alsheikh R, Namnqani S, Al-Mohammadi A and Elmorsy S, et al. Effect of simvastatin and atorvastatin on serum vitamin d and bone mineral density in hypercholesterolemic patients: A cross-sectional study. J. Osteoporos. 2014;468397.
Yavuz B, Ertugrul D. T, Cil H, Ata N, Akin K. O and Yalcin A. A, et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: A novel pleiotropic effect of statins? Cardiovasc. Drugs. Ther. 2009;23:295–299.
Ertugrul D. T, Yavuz B, Cil H, Ata N, Akin K. O and Kucukazman M, et al. STATIN-D study: Comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovasc. Ther. 2011;29:146–152.
Sathyapalan T, Shepherd J, Arnett C, Coady A. M, Kilpatrick E. S and Atkin S. L. Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clin. Chem. 2010;56:1696–1700.
Pérez-Castrillón J. L, Abad L, Vega G, Sanz-Cantalapiedra A, García-Porrero M and Pinacho F, et al. Effect of atorvastatin on bone mineral density in patients with acute coronary syndrome. Eur. Rev. Med. Pharmacol. Sci. 2008;12:83–88.
Descamps O. S, De Sutter J, Guillaume M and Missault L. Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today? Atherosclerosis. 2011;217:308–321.
Wido, A., Bajamal, A. H., Apriawan, T., Parenrengi, M. A., & Al Fauzi, A. (2022). Deep vein thrombosis prophylaxis use in traumatic brain injury patients in tropical climate. International Journal of Health & Medical Sciences, 5(1), 67-74. https://doi.org/10.21744/ijhms.v5n1.1840
Van Himbergen T. M, Matthan N. R, Resteghini N. A, Otokozawa S, Ai M and Stein E. A, et al. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. Lipid. Res. 2009;50:730–739.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949
Hui D. Y, Labonté E. D and Howles P. N. Development and physiological regulation of intestinal lipid absorption. III. Intestinal transporters and cholesterol absorption. Am. J. Physiol. Gastrointest. Liver. Physiol. 2008;294:839–843.
Reboul E, Goncalves A, Comera C, Bott R, Nowicki M and Landrier J. F, et al. Vitamin D intestinal absorption is not a simple passive diffusion: Evidences for involvement of cholesterol transporters. Mol. Nutr. Food. Res. 2011;55:691–702.
Liberopoulos E. N, Makariou S. E, Moutzouri E, Kostapanos M. S, Challa A and Elisaf M. Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin D levels. Cardiovasc. Pharmacol. Ther. 2013;18:229–233.
Ritu G and Gupta A. Vitamin D deficiency in India: Prevalence, causalities and interventions. Nutrients. 2014;6:729–735.
Bhattacharyya S, Bhattacharyya K and Maitra A. Possible mechanisms of interaction between statins and vitamin D. QJM. 2012;105:487–491.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
